{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:42:37Z","timestamp":1783539757437,"version":"3.55.0"},"reference-count":41,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Digest Diseases"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To characterize the pattern of positive conversion of interferon gamma release assay (IGRA) in patients with Crohn's disease (CD) during infliximab therapy in China, which has a high burden of tuberculosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eligible patients with CD who received serial IGRA screening during infliximab therapy from January 2015 to March 2020 were retrospectively included. The positive conversion rate of IGRA and the risk of subsequent tuberculosis of the patients were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 128 patients with CD were included, and the median time from the initiation of IFX treatment to positive conversion or the last follow\u2010up test of IGRA was 43.6\u2009weeks. At baseline 3.9% of the patients were positive for IGRA and received prophylactic anti\u2010tuberculosis treatment. In the other 123 patients with negative IGRA at baseline, 6.5% had IGRA positive conversion during infliximab treatment, and one (12.5%) who was exposed to <jats:italic>Mycobacterium tuberculosis<\/jats:italic> was diagnosed as having active tuberculosis. The conversion rate at 40\u2009weeks, 2\u2009years and 3\u2009years after treatment were 10.0% (6\/60), 2.2% (1\/46) and 5.9% (1\/17), respectively. Age, sex, history of smoking and alcohol consumption, disease severity (Crohn's disease activity index score) and immunosuppressive therapy were not significantly associated with latent tuberculosis test conversion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Positive conversion of IGRA occurs early during treatment with infliximab for CD and the monitoring frequency of IGRA should be appropriately increased at the early stage of treatment. Physicians should pay attention to patient's history of tuberculosis exposure and carry out surveillance in a timely fashion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1751-2980.13032","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T11:50:06Z","timestamp":1625831406000},"page":"473-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with <scp>Crohn's<\/scp> disease"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-4733","authenticated-orcid":false,"given":"Qin Yu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9055","authenticated-orcid":false,"given":"Cheng Dang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology First Affiliated Hospital of Fujian Medical University  Fuzhou Fujian Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i25.2764"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4620"},{"issue":"6","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","article-title":"Structural deficiencies in granuloma formation in TNF gene\u2010targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin","volume":"162","author":"Bean AGD","year":"1999","journal-title":"J Immunol."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/593174"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","author":"American Thoracic Society\/Centers for Disease Control and Prevention","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw022"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15196"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"issue":"1","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the Study of Inflammatory Bowel Disease (IG\u2010IBD) Clinical Practice Guidelines: The use of tumor necrosis factor\u2010alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando A","year":"2011","journal-title":"Dig Liver Dis."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7132875"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy057"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2019.1690676"},{"issue":"7","key":"e_1_2_7_19_1","first-page":"283","article-title":"Spectrum of anti\u2010neutrophil cytoplasmic antibodies in patients with pulmonary tuberculosis overlaps with that of Wegener's granulomatosis","volume":"58","author":"Pradhan VD","year":"2004","journal-title":"Indian J Med Sci."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002665"},{"issue":"3","key":"e_1_2_7_21_1","first-page":"306","article-title":"Auto\u2010antibody profiles in patients with active pulmonary tuberculosis","volume":"11","author":"Elkayam O","year":"2007","journal-title":"Int J Tuberc Lung Dis."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14648"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12037"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.2.173"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.05.012"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2016.14.2.146"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00023"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06899-1"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163642"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13669"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0252"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000147"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207811"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.11.038"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v5i1.349"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2049-6"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200489"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04510-6"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-13"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040192"},{"key":"e_1_2_7_41_1","unstructured":"European Centre for Disease Prevention and ControlUse of interferon\u2010gamma release assays in support of TB diagnosis. Stockholm: ECDC; 2011."},{"key":"e_1_2_7_42_1","unstructured":"National Institute for Health and Clinical Excellence. Tuberculosis. Availabe from:https:\/\/www.nice.org.uk\/guidance\/ng33\/resources\/tuberculosis-pdf-1837390683589."}],"container-title":["Journal of Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.13032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1751-2980.13032","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.13032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:00:13Z","timestamp":1693288813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1751-2980.13032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/1751-2980.13032"],"URL":"https:\/\/doi.org\/10.1111\/1751-2980.13032","archive":["Portico"],"relation":{},"ISSN":["1751-2972","1751-2980"],"issn-type":[{"value":"1751-2972","type":"print"},{"value":"1751-2980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2020-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}